Zofran-drug group antiemetics. Its distinctive feature is that it has no sedative effect.
Indications and dosage.
Elimination and prevention of nausea and vomiting caused by holding zitostaticescoy chemotherapy or radiotherapy; prevention and removal of postoperative nausea and vomiting.
For prevention and elimination of nausea and vomiting in zitostaticescoy chemotherapy or radiotherapy dosage selection is determined by the èmetogennost′û antitumor therapy. Daily dose for adults is usually 8-32 mg. When chemotherapy and radiotherapy umerennoèmetogennoj recommended dose is 8 mg ondansetron for 1-2 hours before the start of the main therapy followed by another 8 mg in 12:00 When high emetogenic chemotherapy recommended dose of 24 mg ondansetron simultaneously with reception inside the dose of dexamethasone 12 mg for 1-2 hours before the start of chemotherapy.
To prevent late or prolonged vomiting that occurs through 24 h reception Zofran should continue at a dose of 8 mg 2 times per day for 5 days.
Children ondansetron usually injected as a solution for injection in one/in just before the start of chemotherapy followed by Zofran inside the dose of 4 mg via 12:00 after the end of chemotherapy should continue receiving syrup at a dose of Zofran 4 mg 2 times per day for 5 days.
For prevention and elimination of nausea and vomiting in postoperative period adults recommend admission of 16 mg Zofran for 1 h prior to the holding of narcosis. For postoperative nausea and vomiting heavily recommend the use of ondansetron in the form of solution for the on/in the injections.
Children to prevent and relieve postoperative nausea and vomiting ondansetron assign as a solution for injection.
When applying changes in the elderly dosage is not required. When kidney failure requires no special correction dose, frequency or mode of application.
In appointing drug patients with impaired liver daily dose should not exceed 8 mg.
In the appointment Zofran patients with slow metabolism sparteina/debrisokvina correction daily dose or frequency of admission is not required.
Method of application.
Zofran for resorption should not squeeze the foil. Tablets from the packaging should get immediately before use. Tablet for resorption placed at the tip of the tongue, after dissolution of her need to swallow.
There is limited data on overdose of ondansetron.
Symptoms: in most cases, the symptoms are similar to adverse reactions when use of the drug in the recommended doses. Treatment: a simptomaticescuu therapy specific antidote not. Apply ipekakuanu overdose Zofran should not, because the effectiveness of its unlikely.
Side effects Zofran.
On the part of the digestive system: hiccup, dry mouth, constipation or diarrhea. Sometimes asymptomatic transient increased liver enzymes.
Cardiovascular system: chest pain, in some cases with ST-segment depression, arrhythmia. aetiology, decline ad.
From the central nervous system: headache, dizziness, spontaneous movement disorders and convulsions, temporary violation of Visual acuity.
allergic reactions: urticaria. bronchospasm, laryngospasm, angioedema. anaphylaxis.
Other: the tide of blood to a person, a sense of heat, gipokaliemia, gipercreatininemia.
- children up to 2 years of age (the safety and effectiveness of the studied);
- hypersensitivity to the drug component.
In some cases in persons with a history of sensitivity to other serotonin antagonist 5НТ3-retseptorov, marked by an allergic reaction to ondansetronu.
As ondansetron increases travel time content on the large intestine, after applying the product requires special monitoring of patients with signs of bowel obstruction. Be wary appoint with pills for resorption in patients with phenylketonuria in connection with the presence of aspartame.
Interactions with other drugs and alcohol.
there is no evidence that ondansetron induces or inhibits the metabolism of other drugs commonly prescribed in combination with it.
Ondansetron is metabolized by multiple cytochrome P450 system izofermentami (CYP3A4, CYP2D6 and CYP1A2). Oppression or reduced activity of one of the enzymes is usually normal offset by others, and therefore a significant reduction in the total clearance of ondansetron is unlikely. The likelihood of interaction and exercise caution when coupled with ondansetron inducers of CYP3A and CYP2D6, such as barbiturates, carbamazepine, karizoprodol, glutetimid, griseofulvin, nitrous oxide, papaverine, fenilbutazon, phenytoin (and probably other gidantoin), rifampicin, tolbutamid; as well as inhibitors of CYP3A and CYP2D6, such as allopurinol, macrolide, antidepressants, MAO inhibitors, chloramphenicol, zimetidin, oral contraceptives èstrogenosoderžaŝie, diltiazem, disulfiram, sodium valproate, valproic acid, fluconazole, Fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranolol, quinidine, quinine, verapramil.According to special studies found that ondansetron does not interact with ethanol, temazepamom, furosemide, tramadolom and propofol.
Zofran for resorption white, round, convex on one side and flat on the other side.
1 tab. ondansetron 4 mg, 8 mg-LF “excipients: gelatin, mannitol, aspartame, sodium methyl hydroxybenzoate, sodium propilgidroksibenzoat, strawberry flavoring, purified water.
10 PCs. -blisters (1)-packs of cardboard.
Anti-emetic drug, selective serotonin antagonist 5НТ3-receptors.
the action relates to the Suppression of gagging by blockade of serotonin receptors at the level of 5НТ3 neurons in both the Central and peripheral nervous system. This mechanism of action was founded on prevention and treatment of post-operative and zitostaticescoy chemotherapy and radiotherapy of vomiting and nausea associated with increased levels of serotonin, which by activation of afferent vagusnyh containing 5НТ3-fiber receptors, causes the gag reflex.
the drug should be kept out of the reach of children at a temperature below 30° c. Shelf life-3 years.